X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Zeposia (ozanimod) is an oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5. It is indicated for the treatment of relapsing forms of multiple sclerosis.
Lead Product(s): Ozanimod
Therapeutic Area: Neurology Product Name: Zeposia
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
Idhifa (enasidenib) is an isocitrate dehydrogenase-2 inhibitor, which is being evaluated in combination with venetoclax for the treatment of IDH2 gene mutated acute myeloid leukemia.
Lead Product(s): Enasidenib,Venetoclax
Therapeutic Area: Oncology Product Name: Idhifa
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
Pursuant to the terms of the settlement, Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain limited quantity of generic lenalidomide capsules in the US beginning on a confidential date that is sometime after March 2022.
Lead Product(s): Lenalidomide,Dexamethasone
Therapeutic Area: Oncology Product Name: Revlimid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sun Pharmaceutical Industries Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
